AU2476001A - Tea tree oil formulations - Google Patents

Description

P/00/011 Regulation 3.2

AUSTRALIA

Patents Act 1990

ORIGINAL

COMPLETE SPECIFICATION STANDARD PATENT Invention Title: "TEA TREE OIL FORMULATIONS" The following statement is a full description of this invention, including the best method of performing it known to me/us: 2

TITLE

"TEA TREE OIL FORMULATIONS" THIS INVENTION relates to improving the treatment efficiency of tea tree oil when used as a therapeutic agent.

Tea tree oil when used as a therapeutic agent has antifungal activity as reported in Nenoff et al, Skin Pharmacol 9 388- 394 (1996). In this reference tea tree oil was found to inhibit growth of clinical fungal isolates including Candida sp including Candida albicans which causes candidiasis of skin, mucous membranes and nails, Malassezia furfur which causes pityriasis versicolor, follicular pityriasis, seborrhoeic dermatitis and pityriasis capitis severe dandruff) and Trichosporon rubrum, Trichosporon mentagrophytes and Microsporum canis, which cause ringworm or tinea of scalp, skin (in particular glabrous or hairless skin) and nails. As discussed in Ellis 15 and Watson, Aust. Prescr. 19; 3; 72-74 (1996) these infections can be considered to be broadly classified as cutaneous fungal infections.

oo Such infections are usually treated topically, but nail and hair infections, widespread dermatophytosis and chronic non responsive yeast infections are best treated with oral antifungal drugs which are 20 conventional drugs including griseofulvin, ketoconazole, fluconazole, itraconazole and terbinafine.

However, as stated in the Ellis and Watson reference, the major disadvantage of the use of systemic therapy using the 3 above drugs, which are taken orally, is of potential adverse effects as well as cost considerations which apply to the newer systemic antifungal drugs. It is also known that some drugs have limited areas of application. For example, in the case of griseofulvin, this drug is active against dermatophytes, but has no effect against yeasts or other fungi.

It is also reported in the Nenoff et all article supra that tea tree oil also has therapeutic activity against several bacterial infections inclusive of Staphylococcus aureus, E coli and Propionibacterium acnes.

Reference also may be made to Concha et al, Journal of the American Podiatric Medical Association 88; 10; 489-492 (1998) which states that tea tree oil is receiving much attention as a natural remedy for bacterial and fungal infections of the skin and mucosa as 15 discussed above. Concha et al also advises that tea tree oil has therapeutic activity against bacterial infections caused by Pseudomonas aeruginosa and Staphylococcus epidermidis. Carson et al, J. Antimicrob. Chemother. 35 421- (1996) states that tea tree oil has a wide spectrum of antimicrobial activity and is relatively non 20 toxic when applied topically.

In Bassett et al, Med. J. Aust. 153 455 (1990) tea tree •o oil was reported to have a significant effect in ameliorating acne with fewer side effects in comparison with benzoyl peroxide. Concha et al 4 supra advises that tea tree oil appears to be effective in treatment of tinea pedis, bromhidrosis and other inflammatory foot problems.

Other clinical investigations have been conducted on the use of tea tree oil for onchomycosis, furunculosis, trichomonal vaginitis and oral gingivitis.

However, tea tree oil has received a lot of attention in relation to treatment of diseases caused by M. furfur discussed above and in particular seborrhoeic dermatitis and severe dandruff. Hammer et al, Antimicrob. Agents Chemother. 44; 2; 467-469 (2000) reports that tea tree oil may be a suitable alternative topical agent for Malassezia infections to ketoconazole which was found to be more active than other drugs micronazole and econazole in treatment of Malassezia infections. This reference supports the view that many *patients may prefer the use of tea tree oil as a natural remedy when 15 used topically as opposed to clinical drugs such as ketoconazole. A similar finding was made in Hammer et al, Journal of Medical and Veterinary Mycology 35 375-377 (1997) which stated that although ~skin conditions involving M. furfur can be treated topically with agents such as zinc pyrithione, selenium sulphide and coal tar, or 20 systemically with ketoconazole, itaconazole or fluconazole, the use of tea tree oil as a topical agent may be used where other treatments have failed, where prophylaxis is required or simply as an alternative therapy.

A major infection of commercial significance as described above which is caused by M. furfur is seborrhoeic dermatitis and dandruff (otherwise called pityriasis capitis) which is seborrhoeic dermatitis of the scalp. Dandruff itself is not a disease, but may be symptomatic of hair loss and even baldness. Dandruff can also be embarrassing, leading to fine particles or "snowflakes" appearing on clothes, especially in the shoulder region. The usual symptoms of dandruff include a dry, flaky scalp or itchy waxy scales that stick to the hair, which may cause severe irritation. Dry dandruff usually indicates insufficient brushing of the hair or poor circulation of blood to the scalp. Waxy dandruff may result from overactive sebaceous glands. Severe dandruff may indicate psoriasis.

Conventional shampoos that have been used to control or reduce dandruff, which include anti-dandruff agents such as selenium sulfide, zinc pyrithione or coal tar are deficient because such anti-dandruff agents are toxic if used in excess and can cause scalp 0 irritation. One solution to these problems is to reduce the amount of anti-dandruff agent but this may lead to decreased effectiveness in 00..

use.

.o 20 Tea tree oil has also been used in shampoos in relatively dilute concentrations which may be from Tea tree oil possess at least 48 organic compounds, having both antiseptic and antifungal properties and has therefore been incorporated in products 6 for treatment of a variety of skin disorders, including dandruff. Such shampoos have been described as having anti-dandruff properties but this is speculative and unsupported by efficacy data.

These conventional tea tree shampoos also have a percentage of surfactant solids in the formulation of 20-50% w/v.

These tea tree oil shampoos are sold in Australia under the THURSDAY PLANTATION trade mark. Tea tree oil as stated above is considered to be advantageous when compared to the conventional treatments described above because it is a natural product and therefore considered to be non toxic. Tea tree oil as stated above has also been shown to be useful in treatment of other yeast and fungal infections such as tinea pedis and in this regard has a minimum inhibitory concentration of 0.25% v/v as reported in Tong et al Aust.

J. Dermatol (1992) 33 145-9.

DE 19800982 refers to an ointment for treatment of dandruff, which comprises a mixture of essential oils, inclusive of evening primrose oil, tea tree oil, lavender oil, cod liver oil, borage oil, oooo° •jojoba oil, nutmeg oil and D-panthenol in a lanolin base. However, this ointment is relatively expensive and is not intended for use as a shampoo.

D129913476 refers to a composition for treating skin :*disorders inclusive of dandruff containing tea tree oil, bay-tree oil, peppermint oil and isopropanol and is also not intended for use as a shampoo.

US5750108 refers to a hair treatment system and kit for invigorating hair growth, which involves use of a first treatment comprising tea tree oil and a second treatment comprising chlorine dioxide. This method is relatively complicated and is not intended for use as a shampoo.

One problem, which has been ascertained by the present inventors, that is associated with the use of tea tree oil therapeutic products such as anti-dandruff shampoos, is that the level of surfactant in such shampoos may adversely effect the active or nonbound level of tea tree oil in the shampoo. If the level or surfactant is excessive, then it may bind the tea tree oil in a surfactant matrix which will mean that there is insufficient concentration of free or nonbound levels of tea tree oil to be effective in use. In this regard it will be appreciated that when tea tree oil shampoos or other products containing tea tree oil are being formulated that a level of surfactant is included to allow for emulsification of the tea tree oil and also to ooeee retain relevant foaming and/or cleansing characteristics which are satisfactory to the consumer.

e It is therefore an object of the invention to provide a therapeutic formulation containing tea tree oil which alleviates the problem described above.

The formulation of the invention comprises a 8 concentration of tea tree oil of 0.25-15% w/v and a total surfactant concentration of 1-15% w/v.

It has now been found, in accordance with the invention, that if the surfactant concentration is maintained between 1-15% w/v, for therapeutic products having a tea tree oil concentration of 0.25-15% w/v, then significant amounts of the tea tree oil present in the formulation is in free or non bound form i.e. it is not bound to the surfactant and thus is in an "active" concentration.

The invention also provides a method of increasing the efficiency of action of use of tea tree oil as a therapeutic which includes the step of providing a formulation which provides a maximum concentration of unbound or free tea tree oil in a surfactant wherein the level of surfactant is maintained at a maximum concentration of 15% w/v.

15 The term "tea tree oil" as used herein includes not only tea tree oil per se i.e. in its natural form as well as one or more active components thereof e.g. terpinen-4-ol and/or alpha terpineol. The •term "tea tree oil" as used herein refers to natural forms of tea tree oil which are obtained from any appropriate Melaleuca species or g 20 Leptospermum species such as, for example, M.alternifolia, M.linariifolia and M.dessitafolia, as well as modified extracts containing the aforementioned active components per se.

It also will be appreciated that the composition of the 9 invention may also include other topical active components which include zinc pyrithione, sulphur, selenium sulphide, coal tar, salicylic acid and piroctone olamine. These additional components may be present in a concentration of 0.1-2.0% w/v.

It also will be appreciated that the formulation of the invention may be utilised for any therapeutic effect known in the art which may be achieved by tea tree oil such as the abovementioned anti-fungal or antibacterial applications. The formulation of the invention may also be used as a mouthwash, cream, shampoo or any other suitable topical usage. The formulation of the invention may also be used for veterinary purposes such as a pet shampoo as well as for application to humans.

Surfactants useful as shampoos are described in "HARRY'S COSMETICOLOGY" Seventh Edition (1982) Chemical Publishing Company of the USA which publication is totally incorporated herein by reference. The surfactants useful for inclusion in shampoos may include principal surfactants to provide detergency •and foam and auxiliary surfactants to provide detergency, foam, and hair condition. Principal surfactants may comprise non-ionic surfactants or cationic surfactants, but it is usually preferred to use anionic surfactants because of their superior foaming properties and lower cost. Such anionic surfactants may include soaps i.e. metallic or alkanolamine salts of fatty acids, alkyl benzene sulfonates, C 14 16 alpha olefin sulfonates, or alkyl sulfates especially those derived from lauryl and myristyl alcohols. Lauryl sulfates give a greater volume of lather and myristyl sulfates greater richness. The most popular anionic surfactants are sodium lauryl sulfate, sodium lauryl ether sulfate or ammonium lauryl sulfate. Use also may be made of alkyl polyethylene glycol sulfates or alkyl ether sulfates sulfosuccinates, monoglyceride sulfates, fatty glyceryl ether sulfonates, isethionates, methyl laurides, acyl sarcosinates, acyl peptides, acyl lactylates or polyalkoxylated ether glycollates.

Nonionic surfactants are usually used as additives to anionic surfactants and may include C12-18 monoethanolamides or isopropanolamides which are used in conjunction with lauryl sulfates on a basis of 1-15 parts per 100 parts of anionic surfactant.

Diethanolamides may also be used as well as polyalkoxylated derivatives including ethoxylated fatty alcohols, ethoxylated alkyl phenols, ethoxylated fatty amines and fatty acid amides, poloxamers, sorbitol esters, polyglyceryl ethers or amine oxides.

Amphoteric surfactants also are generally used as auxiliary surfactants inclusive of long chain substituted amino 20 acids such as sodium cocaminopropionate, or derivatives and long chain betaines inclusive of amidobetaines or long chain imidazoline derivatives.

Particularly preferred principal surfactants are ammonium 11 lauryl sulfate, sodium ether lauryl sulfate and triethanolamine lauryl sulfate. Particularly preferred auxiliary surfactants are cocamide DEA and cocoamidopropyl betaine. These surfactants when mixed together compliment each other in terms of cleansing, foaming, thickening and emulsification.

EXPERIMENTAL

EXAMPLE 1 This was a randomised, single blind, parallel group study investigating the efficiency and tolerability of tea tree oil in concentrations of 2.5% and 1% zinc pyrithione and placebo in patients with mild to moderate dandruff. The 1% zinc pyrithone formulation was a conventional dandruff shampoo marketed 15 under the ZP11 trade mark. Relevant formulations containing tea tree oil were as follows: oil were a's follows: o 1.0% tea tree oil formulation Tea Tree (Melaleuca Alternifolia) Oil Castor Oil (surfactant) Antioxidant Fragrance Sodium Laureth Sulfate (surfactant) Cocoamidopropyl Betaine (surfactant) Thickener Pearling Agent Preservative Purified Water 1.00% 2.00% 0.20% 0.50% 14.00% 4.50% 0.80% 3.00% 0.50% 73.50% 100.00% 2.5% tea tree oil formulation 9**

S

S. S 55 55

SSSS

'Sr 5

SSSS

5S S S

S

5

S

Tea Tree (Melaleuca Alternifolia) Oil PEG-35 Castor Oil (surfactant) Antioxident Fragrance Sodium Laureth Sulfate (surfactant) Cocoamidopropyl Betaine (surfactant) Thickener Pearling agent Preservative Purified Water 2.50% 5.00% 0.20% 0.50% 14.00% 4.50% 1.70% 3.00% 0.50% 68.10% 100.00% 13 5.0% tea tree oil formulation Tea Tree (Melaleuca Alternifolia) Oil Castor Oil (surfactant) Antioxidant Fragrance Sodium Laureth Sulfate (surfactant) Cocoamidopropyl Betaine (surfactant) Thickener Pearling agent Preservative Purified Water 5.00% 10.00% 0.20% 0.50% 14.00% 4.50% 1.90% 3.00% 0.50% 60.40% 100.00%

S

*5

S

S

S. S

S

*r

S.

S S

S.

S.

S.

Demography One hundred and fifty eight subjects were enrolled in the study and randomised to receive one of five possible study medications as described above. Thirty-two subjects were randomised to each of the 1% Tea Tree Oil, 1% zinc pyrithione and placebo groups and thirty-one subjects to each of the 2.5% Tea Tree Oil and 5% Tea Tree Oil groups.

The age of the subjects ranged from 15 to 77 years (with a mean age 32 years). Ninety-three subjects were male and the vast majority (107 subjects, 68%) where classified as white (caucasian).

Efficacy The efficacy measures were based on the precent change, from baseline (ie Week in the whole Scalp Score as well as the three components of the Patient Self Assessment. Percent change was calculated as follows: Percent change Visit Value Baseline Value Baseline Value x 100 Whole Scalp Score Lesions were examined and scored on a quadrant-areaseverity scale. The scalp was divided into four quadrants. The area of involvement of each quadrant will be measured on a 1-5 scale where: 15 1 less than 10% involvement, S2 =10-30% involvement, 3 30-50% involvement, 4 50-70% involvement and 5 more than 70% involvement.

20 The total area of involvement was obtained by adding the four quadrant scores.

Severity was measured by a 0-3 scale where: 0 indicates healed 1 mild 2 moderate 3 severe.

The total severity score will be obtained by adding the four quadrant scores.

The whole scalp lesion score will then be obtained by multiplying the total area of involvement by the total severity score.

RESULTS

It was found that the percent change values exhibit relatively high variability and also that the values are not symmetrically distributed (since the mean and median values are often substantially different). For this reason the analysis included both parametric and non-parametric methods. The largest percent decrease in the Whole Scalp Score was exhibited by subjects receiving 1% zinc pyrithione (a median percent reduction of 43%) and 15 the smallest percent decrease was exhibited by subjects receiving 2.5% Tea Tree Oil (a median percent reduction of After S"making adjustments for multiple testing, there were no statistically 0significant differences between the treatment groups with respect to *5*S percent change from baseline to Week 4 in the Whole Scalp Score.

20 Patient Self Assessment •o•,o Patients were requested to make a self-assessment at each visit for the following parameters: skin scalp scaling, itching and greasiness on a 100 mm visual analogue scale, with the two 16 extremes being "none" and "worst ever".

Scaling It was found that the largest percent decrease in the Scaling Score was exhibited by subjects receiving 1% zinc pyrithione (a median percent reduction of 48%) and the smallest percent decrease was exhibited by subjects receiving placebo (a median percent reduction of After making adjustments for multiple testing, there were no statistically significant differences between the treatment groups with respect to percent change from baseline to Week 4 in the Scaling Score.

Itching It was found that the largest percent decrease in the Itching Score was exhibited by subjects receiving 5% tea tree oil (a ooo median percent reduction of 54%) and the smallest percent decrease esee 0S 15 was exhibited by subjects receiving placebo (a median percent *°oooo o reduction of After making adjustments for multiple testing, *000 °there were no statistically significant differences between the ~treatment groups with respect to percent change from baseline to OS e 6•OO O O Week 4 in the Itching Score.

°0 20 Greasiness 00*@ agog 0 ooee It was found that the largest percent decrease in the 0 Ge Greasiness Score was exhibited by subjects receiving placebo (a median percent reduction of 48%) and the smallest percent decrease 17 was exhibited by subjects receiving 1% tea tree oil (a median percent reduction of After making adjustments for multiple testing, there were no statistically significant differences between the treatment groups with respect to percent change from baseline to Week 4 in the Greasiness Score.

EXAMPLE 2 126 male or female patients aged 14 or older were recruited to a randomised, single blind, parallel group study with the objective of investigating the efficacy and tolerability of 5% tea tree oil (TTO) and placebo, in patients with mild to moderate dandruff.

At the initial study visit patients underwent a medical examination, and patients who satisfied the study eligibility criteria and consented to participate were randomised to daily applications of either 5% tea tree oil or placebo, over a four-week period. Patients 15 were assessed after two and four weeks of study medication. At o*o.

each visit, including the initial study visit, the lesions were examined and scored on a quadrant-area severity scale. In addition, patients were required to record their own assessment of skin scaling, itching S. and greasiness on a visual analogue scale.

•o A total of 126 patients were enrolled in the study with ~63 patients randomised to each medication. The 5% tea tree oil formulation comprised the following: 18 Tea Tree (Melaleuca Alternifolia) Oil 5.00% Cocamide DEA (surfactant) 8.00% Ammonium Lauryl Sulfate (surfactant) 5.40% Pearling agent 0.50% Purified Water 81.10% 100.00% The primary efficacy parameter in this study was the percentage change in the whole scalp lesion score from Baseline (Week O) to after the end of the study medication period. The primary comparison was between 5% tea tree oil and the placebo group patients.

The score for total area of involvement, total severity and whole scalp lesion (total area of involvement x total severity oooo 15 score) at Week 0 was summarised for all patients enrolled, by treatment group and overall.

Patient self assessment of scalp scaling, itching and greasiness on a 100 mm visual analogue scale (O=none and 100 worst ever) at Week 0 was summarised for all patients enrolled, 20 by treatment group and overall.

o* ~Primary Efficacy Analysis ***The primary efficacy variable was the mean percentage change in the whole scalp lesion score, from Week 0 (Baseline), to the patient's last assessment (Endpoint).

The percentage change from Week 0 in the whole scalp 19 lesions score, in addition to the actual score at Weeks 0, 2, 4 and at Endpoint, was summarised for both the Intention-to-Treat population and the efficacy evaluable population.

The percentage change from Week 0 to Endpoint in the group of patients treated with 5% tea tree oil was compared with the placebo group using Analysis of Variance. A 95% confidence interval for difference in mean percentage change, between the two treatment groups, was presented.

Secondary Efficacy Analyses The total area of involvement score, and the total severity score were summarised (actual values and percentage change from Week 0) in an identical manner to that described above for the whole scalp lesions score. The percentage change from Week 0 to Endpoint was compared between treatment groups, also using the same methodology described in the previous section.

Patient Self Assessment The primary tolerability measure was the change in each eeo* of the three components of the patient's self assessment (scaling, itching, and greasiness of scalp), from Week 0 (Baseline), to the patient's last assessment (Endpoint).

The actual scores at Weeks 0, 2, 4 and at Endpoint and the change from Week 0 for each of the three components of the patient's self assessment (scaling, itching and greasiness of scalp) at Weeks 2, 4 and at Endpoint were summarised. The change from Baseline at Endpoint was compared between treatment groups using a two-sampled t-test ANOVA since the data satisfies the underlying assumptions for this parametric test.

RESULTS

Primary Efficacy Table 1 presents the primary efficacy results based on the Intention-to-Treat population, by treatment group. The results of Table 1 are also shown in FIG. 1.

The mean percentage decrease from Baseline to Endpoint in whole Scalp Lesion Score was 41.17% in the 5% tea tree oil treatment group compared to 11.16% for the placebo group.

There was a high statistically significant mean difference between 5% tea tree oil and the placebo treatment group (-30.01%, p-value <0.001). The 95% confidence interval, comparing 5% tea tree oil with placebo was -44.15% to -15.87%. This does not include 0, which enforces the conclusion drawn from the p-value "00" regarding the statistically significant mean difference.

Results for the primary efficacy parameter based on the efficacy evaluable population are presented in Table 2.

For this population the mean percentage decrease from Baseline to Week 4 in Whole Scalp Lesion Score was 41.7% in the tea tree oil treatment group, compared to 10.5% in the placebo group at the Week 4 visit.

There was a statistically significant mean difference between 5% tea tree oil and the placebo treatment group (-31.17, pvalue <0.001). The 95% confidence interval of this mean difference [-45.37, -16.98] does not include 0, which enforces the conclusion drawn from the p-value regarding the statistically significant mean difference.

Secondary Efficacy Tables 3 and 4 present the secondary efficacy results based on the Intention-to-Treat population, by treatment group.

The mean percentage decrease from Baseline to Endpoint in Total Area of Involvement Score was 28.30% in the 5% tea tree oil group compared to 12.52% in the placebo group at the Endpoint visit.

The mean percentage decrease from Baseline to Endpoint in Total Severity Score was 23.35% in the 5% tea tree oil group compared to a mean percentage decrease of 2.84% in the placebo ego* ee group, at the Endpoint visit.

For the percentage change in both the Total Area of •ooo Involvement Score and Total Severity Score, there were statistically "significant differences between 5% tea tree oil and placebo groups (pvalues <0.001). The 95% confidence intervals of the respective mean differences, comparing TTO with placebo, (Total Area of 22 Involvement [-24.21, -7.36] and Total Severity [-32.25, do not include 0, which enforces the conclusions drawn from the pvalues suggesting a statistically significant mean difference.

Results for the secondary efficacy parameters based on the efficacy evaluable population are presented in Tables 5 and 6.

For this population the mean percentage decrease from Baseline to Endpoint in Total Area of Involvement Score was 28.4% in the 5% tea tree oil group compared to 12.1% in the placebo group, at Week 4.

For the efficacy evaluable population, the mean percentage decrease from Baseline to Endpoint in Total Severity Score was 23.4% in the 5% tea tree oil group compared to 2.5% in the placebo group, at Week 4.

For the percentage change in both the Total Area of Involvement Score and Total Severity Score, there were statistically significant differences between 5% tea tree oil and placebo groups (pvalues <0.001). The 95% confidence intervals of the respective mean differences, comparing TTO with placebo, (Total Area of Involvement [-24.88, -7.80] and Total Severity [-32.75, do not include 0, which enforces the conclusions drawn from the pvalues suggesting a statistically significant mean difference.

Patient Self Assessment Table 7 presents the secondary efficacy results based on 9* 23 the Intention-to-Treat population, by treatment group.

The mean decrease from Baseline to Endpoint in Scaling of Scalp was 25.6 in the 5% tea tree oil group. This compares to a mean decrease of 16.9 in the placebo group at the Endpoint visit.

This mean difference, between 5% tea tree oil and placebo groups, was statistically significant (p-value: 0.033) at the 5% level of significance.

The mean decrease from Baseline to Endpoint in itching of Scalp was 23.0 in the 5% tea tree oil group. This compares to a mean decrease of 12.1 in the placebo group at the Endpoint visit.

This mean difference, between 5% tea tree oil and placebo groups, was statistically significant at the 5% level of significance (p-value: 0.015).

oooo The mean decrease from Baseline to Endpoint in Greasiness of Scalp was 25.9 in the 5% tea tree oil group. This 00o* compares to a mean decrease of 8.2 in the placebo group at the Endpoint visit. This mean difference, between 5% tea tree oil and placebo groups, was statistically significant at the 1% level of significance (p-value: <0.001).

•o Results for the secondary efficacy parameters based on 0 the efficacy evaluable population are presented in Table 8.

For this population the mean decrease from Baseline to Week 4 in Scaling of Scalp was 25.4 in the 5% tea tree oil group.

24 This compares to a mean decrease of 17.4 in the placebo group at the Week 4 visit. This mean difference, between 5% tea tree oil and placebo groups, was statistically significant at the 5% level of significance (p-value: 0.048).

For the efficacy evaluable population, the mean decrease from Baseline to Week 4 in itching of Scalp was 23.1 in the 5% tea tree oil group. This compares to a mean decrease of 13.0 in the placebo group at the Week 4 visit. This mean difference, between tea tree oil and placebo groups, was statistically significant (pvalue: 0.020) at the 5% level of significance.

The mean decrease from Baseline to Week 4 in Greasiness of Scalp was 26.5 in the 5% tea tree oil group. This compares to a mean decrease of 8.4 in the placebo group at the oooo Week 4 visit. This mean difference, between 5% tea tree oil and placebo groups, was statistically significant (p-value: <0.001) at the 1% level of significance.

CONCLUSIONS ON COMPARISON BETWEEN EXAMPLE 1 AND ~EXAMPLE 2 It was found when evaluating the formulation of 2.5% and 5.0% tea tree oil that total surfactant concentration was calculated to be 20.5%, 24.5% and 29.5%.

Clearly the shampoo with 1.0% tea tree oil and 20.5% total surfactant concentration was representative of prior art shampoos as discussed above and was found to be unsatisfactory in use and did not demonstrate effectiveness when compared to placebo. Also the shampoos with 2.5% tea tree oil and 24.5% surfactant concentration and (ii) 5.0% tea tree oil and 29.5% surfactant concentration were found to be unsatisfactory in use and did not demonstrate effectiveness in use when compared to placebo.

Clearly all shampoos failed in the first clinical trial referred to in Example 1 because of excessive levels of surfactant, which bound the tea tree oil in a matrix of the shampoo and did not allow the tea tree oil to reach the scalp. This is in marked contrast to the 5.0% tea tree oil formulation used in Example 2 which demonstrated a marked effectiveness in use when compared to placebo. This formulation had a total surfactant solids concentration of 13.4% which did not bind go the tea tree oil and thus substantially all of the tea tree oil was able to access the scalp.

000: 0 *0 0 o* 0* o• Page(s) h- 1 +0 are claims pages They appear after the table listings a..

a a a a a a. a a a a a a a a a a a a a a a a a a Reduction In Lesions 0l0 00 0 0E 0

(D

i S. S

S

S

V 0 0

ATTORI

Protocol TTOILDANO2 Table 1 Percentage Change in Whole Scalp Lesion Score Intention-to-Treat Population Visit Statistic Week 2 N Mean

SD

Median Min Max Wee): 4 N Mean

SD

Median Min Max Endpoint N Mean

SD

Median Min Max <-Treatment Group TTO PLACEBO Mean Difference 95% CI P-value 63 -23.25 34.34 -25.00 -84.6 69.7 63 -41.17 35.60 -47.50 -100.0 52.7 63 -41.17 35.68 -47.50 -100.0 52.7 62 -5.86 39.50 -5.77 -81.8 120.0 62 -11.16 43.85 -13.25 -100.0 113.3 62 -11.16 43.85 -13.25 -100.0 113.3 -30.01 (-44.15,-15.87) <0.001 TTO 51 Tea Tree Oil.

p-value from Analysis of Variance, comparing treatment groups at Endpoint.

Difference in Percent Mean Change from baseline at Endpoint, between TTO and Placebo S951 Confidence Interval of the respective Mean Difference.

Note: Change Visit Value Baseline (Week 0) Value.

Total Scalp Lesion'Score Total area of involvement x Total severity score.

Endpoint Last visit attended.

.6 60* 0: 00* *0 00 .1 :0 5

ATTORI

Protocol TTOILDAN02 Table 2 Percentage Change in Total Area of Involvement Score Intention-to-Treat Population <-Treatment Group Mean Visit Statistic 'ITO PLACEBO Difference *95% CI **P-value Week: N 63 62 Mean -15.79 -7.65 SD 20.80 20.72 Median -18.18 -6.46 Min -69.2 -58.3 Max 28.6 36.4 WeJ: 4 N 63 62 Mean -28.30 -12.52 SD 21.89 25.59 Median -30.00 -7.69 Min -73.3 -64.3 Max 27.3 45.5 c Endpoint N 63 62 Mean -28.30 -12.52 -15.78 (-24.21, -7.36) <0.001 SD 21.89 25.59 Median -30.00 -7.69 Min -73.3 -64.3 Max 27.3 45.5 8TTO 5. Tea Tree oil.

8p-value from Analysis. of variance, comparing treatment'groups at Endpoint.

*Difference in Percent Mean Change from baseline at Endpoint, between TTO and Placebo 951 Confidence Interval of the respective Mean Difference.

Note: Change =Visit Value Baseline (Week 0) Value.

:Endpoint Last visit attended.

S

*5@ 0 4 eQ 0* 6O@

S

S. S 0 0@ 0 0*.

S

5 OS S S 0@ 9

S

S..

S

S 56 0O5 000 S. 5 0O 5 0

SSO

S S

S

ATTORI

Protocol TTOILDANO2 Table 3 Percentage Change in Total Severity Score Intention-to-Treat Population Visit Statistic <-Treatment Group TTO PLACEBO Mean Difference 951 CI P-value

~I

Week 2 N Mean

SD

Med ian Min Max Week 4 N Mean

SD

Med ian Min Max Endpoint N Mean

SD

Med ianr Mi' flay,.

63 -12.2.9 25. 34 -14.29 -60.0 66.7 63 -23.35 31.47 -28.57 -100.0 66.7 63 -23.35 31.47 -28.57 -100.0 66.7 62 -0.98 26.99 0.00 -60.0 83.3 62 -2.84 34.76 0.00 -100.0 100.0 62 -2.84 34.76 0.00 -100.0 100.0 -20.51 (-32.25, -8.78) 0.001 TTO 51 Tea Tree Oil.

p-value from Analysis of Variance, comparing treatment groups at Enidpoint.

Difference in Percent Mean Change from baseline at Endpoint, between TTO and placebo Confidence Interval of the respective Mean Difference.

Note: Change Visit Value Baseline (Week 0) Value.

Endpoint -Last visit attended.

1%

S

ATTORI

Protocol TTOILDAN02 Table 4 Percentage Change in whole Efficacy Evaluable Scalp Lesion Score Population <-Treatment Group Mean Visit Statistic TTO PLACEBO Difference* 95% CI** P-value WJeek: N 60 Mean -23.23 9 SO 35.20 40.10 Median -24.04 -5.77 Min -84.6 -81.8 Max 69.7 120.0 Week 4 N 60 Mean -41.69 -10.52 -31.17 (-45.37,-16.98) <0.001 SO 34.00 43.90 Median -46.96 -13.25 Min -100.0 -100.0 Max 52.7 113.3 TTO 5% Tea Tree Oil.

9p-value from Analysis of Variance, comparing treatment groups at Week 4.

Difference un Percent Mean Change from baseline at Endpoint, between TTO and Placebo Confidence Interval of the respective Mean Difference.

lluL' Changje Visit Value Baseline (Week 0) Value.

:Total Scalp Lesion Score =Total area of involvement x Total severity score.

ATTORI

Protocol TTOILDAN02 Table Percentage Change in Total Area of Involvement Score Efficacy Evaluable Population <-Treatment Group Mean Visit Statistic TTO PLACEBO Difference* 95% CI** P-value Week: 2 N 60 Mean -16.12 -7.66 SD 21.19 21.03 Median -18.18 -6.46 Min -69.2 -58.3 NM 28.6 36.4 Week 4 N 60 Mean -20.44 -12.10 -16.34 (-24.80, -7.80) -0.001 SD 21.88 25.23 Median -30.00 -7.69 Min -73.3 -64.3 Max 27.3 45.5 TTO Tea Tree Oil.

8p-value from Analysis of Variance, comparing treatment groups at Week 4.

*Difference in Percent Mean Change from baseline at Endpoint, between TTO and Placebo S957. Confidence Interval of the respective Mean Difference.

Ioe:Change -Visit Value Baseline (Week 0) Value.

ATTOPJ

Protocol TTOILDIAN02 Table 6 Percentage Change in Total Severity Score Efficacy Evaluable Population <-Treatment Group Mean visit Statistic TTO PLACEBO Difference* 95% CI** P-value Wee)' 2 N 60 Mean -12.15 -1.10 SD 25.06 29.44 Median -14.29 0.00 Min -60.0 -60.0 Max 66.7 03.3 Week 4 N 60 Mean -23.43 -2.51 -20.92 (-32.75, -9.09) 0.001 SD 30.00 35.22 Median -28.57 0.00 Min -100.0 -100.0 Max 66.7 100.0 TTO 5% Tea Tree Oil.

0p-value from Analysis of variance, comparing treatment groups at Week 4.

*Difference in Percent Mean Change from baseline at Endpoint, between TTO and Placebo Confidence interval of the respective Mean Difference.

Note: Change Visit Value Baseline (Week 0) Value.

S

S

S..

S S Table 7 Change i~n Patient Self' Assessment Intention-to-Treat Population

ATTORI

Protocol TTOILDAN02 SYMPTOM SCALING OF SCALP Treatment Group visit statistic TTO PLACE130 P-Value Wee: 2 N 60 Mean -17.9 -15.5 1 1 ;1 1 r; Mitt1 -'12 Ma x 26 39 Week 4 N 60 61 Mean -25.6 -16.9 SD 21.91 29.08 Median -26.0 -13.0 Min -79 Max 35 41 Endpoint N 60 61 Mean -25.6 -16.9 0.066 so) 21.91 29.08 Median -26.0 -13.0 Min -79 Max 35 41 TTO 5% Tea Tree Oil.

*p-value from Analysis of Variance, comparing treatment groups at Endpoint.

Note: Change -Visit Value Baseline (Week 0) Value.

:Endpoint =Last visit attended.

S o.

ATTORI

Protocol TTOILDANO2 Table 7 (continued) Change in Patient Self Assessment Intention-to-Treat Population SYMPTOM ITCHING (PRURITUS) OF SCALP <---Treatment Group ii I- i I i r 1"1 I'I.ACEnR P-Vn In W' l 2 N 60 Mran I I SD 19. 93 25.10 Median -15.0 Min -57 -59 Max 29 57 Week 4 N 59 61 Mean -23.0 -12.1 SD 21.20 30.84 Median -26.0 Min -69 -88 Max 40 Endpoint N 60 61 Mean -22.6 -12.1 0.031 SD 21.24 30.84 Median -26.0 Min -69 -88 Max 40 TTO 5% Tea Tree Oil.

p-value from Analysis of Variance, comparing treatment groups at Endpoint.

Note: Change Visit Value Baseline (Week 0) Value.

llll ll i I..r v :il ll r'rl,.

0* Table 7 (continued) Change in Patient Self Assessment Intention-to-Treat Population.

ATTORI

Protocol. rrOtLDIN02 SYMPTOM -GREASINCSS OF' SCALP <---Treatment Group Visit Statistic TTO PLACEBO P-Value Week 2 N 60 Mean -19.4 -8.6 SD 22.49 23.36 Median -17.0 Min -67 -72 Max 33 56 Week 4 N 60 61 Mean -25.9 -8.2 SD 28.07 28.92 Median -26.0 Mi n -92 -87 Max 45 03 1,1ndpoint N 60 61 Mecan -25.9 -0.2 0.001 SD 28.07 28.92 Median -26.0 Min -92 -07 Max 45 03 TT10 5% Tea Tree Oil.

*p-value from Analysis of Variance, comparing treatment groups at Endpoint.

Mete: Chiange Visit Value Baseline (Week 0) Value.

:Endpoint Last visit attended.

Table Change in Patient Self Assessment Efficacy Eva.1.ible Populoatlion SYMPTOM SCALING OF SCALP inr"nl' r:roi1p V irgil l .11 i:1l it' I r' u. l Week 2 N 50 59 Mean -18.3 -15.6 SD 21.24 25.34 Median -18.0 Min -72 Max 26 39

U-)

Week 4 N 58 60 0 Mean -25.4 -17.4 0.096 SD 22.26 29.08 Median -25.5 -14.0 Min -79 Max 35 41 8 TTO 5% Tea Tree Oil.

p-value from Analysis of Variance, comparing treatment groups at Week 4.

Note: Change Visit Value Baseline (Week 0) Value.

ee

ATTORI

PrOtocol TTOILDANO2 'lible 8 (on tJ I u ed) Change in Patient Self Assessment Efficacy Evaluable Population SYMPTOM ITCHINMG (PRURITUS) OF SCALP Visit Statistic T--TreO mn GriPLCBO P-value Week 2 N 58 59 Mean -16.0 -9.6 SD 20.15 23.79 Median -15.0 Mm-57 -59 Max 29 Week I1 N 5,1 Mean -23.1 -13.0 0.040 SD 21.34 30.34 Median -26.0 Mi n -69 -88 Max 40 TTO -51 Tea Tree oil.

p-value from Analysis of Va riance, comparing treatment groups at we e1, 4.

Note: Ch1ange Visit Value Baseline (Week 0) Value.

0 0 0 0 Tal 8 .(continued)0 Tfiable 8 continPoud) io Visit Statistic Treatment Group TTO PLACEBO P-value Week 2 N. 58 59 Mean -19.7 SD 22.72 23.55 Median -17.0 -3 Min -67 -72 Max 33 56 Week, 4 N 5860 Mean -26.5 -8.4 0.001 SD 28.05 2-9.15 Median -26.0 Min -92 -87 Max 15 83 Q TTO 51 Tea Tree oil.

*p-value from Analysis of Variance, comparing treatment groups at Week 4.

Note: Change -Visit Value Baseline (Week 0) Value.

Claims (12)

1. A formulation containing 0.25-15.0% w/v tea tree oil and 1-15% w/v of a surfactant.

2. A formulation as claimed in claim 1 including 0.1-2.0% w/v of other topically active components.

3. A formulation as claimed in claim 2 wherein the topically active components are selected from zinc pyrithione, sulphur, selenium sulphide, coal tar, salicylic acid and piroctone olathine.

4. A formulation as claimed in any preceding claim wherein the surfactant is an anionic surfactant.

A formulation as claimed in any preceding claim wherein the anionic surfactant is selected from sodium lauryl sulfate, sodium lauryl ether sulfate or ammonium lauryl sulfate.

6. A formulation as claimed in any preceding claim 15 containing 0.5-5.0% w/v tea tree oil.

A formulation as claimed in any preceding claim containing from 0.5-2.0% of tea tree oil.

8. A formulation as claimed in any preceding claim wherein the maximum amount of surfactant is 13.4% w/v. 20

9. A formulation as claimed in any preceding claim when used as a mouthwash, cream, or shampoo.

10. A formulation as claimed in claim 9 when used as a shampoo.

11. A formulation as claimed in any one of claims 1-8 when used as an anti-dandruff preparation.

12. A method of increasing the efficiency of active of use of tea tree oil as a therapeutic which includes the step of providing a formulation which provides a maximum concentration of unbound or free tea tree oil in a surfactant wherein the level of surfactant is maintained at a maximum concentration of 15% w/v. C oC... C **C C C.. C C CC* C C C C C CC